Google+ Badge

Thursday, April 16, 2015

Cancer Research: Improved treatment of malignant melanoma ♦ Antifungal drug a potential new cancer treatment ♦ Palliative care in cancer improves patients' lives

Early use of palliative care in cancer improves patients' lives, outcomes for caregivers ignificant improvement has been noted in several measures among those who began palliative care early "Early interventions for caregivers lowered their depression and stress burden in the last month of the patient's life,"
Protein finding can pave way for improved treatment of malignant melanoma For the first time, researchers have linked a new protein with malignant melanomas. The protein is detected in aggressive malignant melanoma cells and might be used to predict whether and how the cancer will spread. At the same time, the discovery also opens new doors for future improved treatment of patients with melanomas.
Molecular signature for outcomes of triple negative breast cancer Compared to other types of breast cancer, triple negative breast cancers are often more aggressive and have fewer treatment options. Researchers have identified a molecular mechanism that triple negative breast cancer cells use to survive and grow, and say that if this result is validated in clinical trials, certain women may be identified at high risk for recurrence early, and could be treated more aggressively.

Antifungal drug shows promise as potential new cancer treatment A common antifungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project. The ReDO project is an international collaboration of anticancer researchers dedicated to promoting the cause of common medicines which may represent an untapped source of novel therapies for cancer. Itraconazole is a drug used to treat a broad range of fungal infections, including skin and nail infections. It also has a lot of potential as a new cancer treatment, according to the ReDo project

No comments:

Post a Comment